

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 31/56, C07C 49/105, 49/293	A1	(11) International Publication Number: WO 95/06472 (43) International Publication Date: 9 March 1995 (09.03.95)
(21) International Application Number: PCT/US94/09852 (22) International Filing Date: 1 September 1994 (01.09.94) (30) Priority Data: 08/123,151 2 September 1993 (02.09.93) US (71) Applicant: HUMANETICS CORPORATION [US/US]; 1107 Hazeltime Gates Boulevard, Chaska, MN 55318 (US). (72) Inventors: LARDY, Henry, A.; 1829 Thorstrand Road, Madison, WI 53705 (US). REICH, Ieva, L.; 514 Edward Street, Madison, WI 53711 (US). YONG, Wei; 3 Lenape Trail, Washington Boro, NJ 07882 (US). (74) Agents: SHERRILL, Michael, S. et al; Faegre & Benson, 2200 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402-3901 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD). Published <i>With international search report.</i>
(54) Title: Δ 5-ANDROSTENES USEFUL FOR PROMOTING WEIGHT MAINTENANCE OR WEIGHT LOSS AND TREATMENT PROCESS		
(57) Abstract A method for promoting weight control by treating a subject with a therapeutic amount of one of the Δ 5-androstenes listed below to stimulate weight control without affecting appetite or inducing the synthesis of sex hormones. Δ 5-Androstenes providing the desired biological activities include: (1) Δ 5-Androstene-3 β ,7 α -diol-17-one, (2) Δ 5-Androstene-3 β -ol-7,17-dione, (3) Δ 5-Androstene-3 β ,7 α ,17 β -triol, (4) Δ 5-Androstene-3 β ,17 β -diol-7-one, (5) Δ 5-Androstene-3 β -acetoxy-7,16,17-trione, (6) Δ 5-Androstene-3 β ,16 α -dihydroxy-7,17-dione, (7) Δ 5-Androstene-3 β -propionyloxy-16 β -acetoxy-7,17-dione, (8) Δ 5-Androstene-3 β ,7 α ,17 β -triol-16-one, (9) Δ 5-Androstene-3 β ,17 β -diol-7,16-dione, (10) Δ 5-Androstene-3 β ,16 α ,17 β -triol-7-one and derivatives thereof wherein one or more of the hydroxyl or keto substituents is a group convertible thereto by hydrolysis.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

**Δ5-ANDROSTENES USEFUL FOR
PROMOTING WEIGHT MAINTENANCE OR WEIGHT
LOSS AND TREATMENT PROCESS**

Field of the Invention

5 The invention relates to the use of
steroids for effecting a desired biological
response. Specifically, the invention relates to a
treatment program using Δ5-androstenes for promoting
weight maintenance and/or weight loss (hereinafter
10 referenced collectively as "weight control").

Background

 The steroid dehydroepiandrosterone (DHEA)
is believed to stimulate various biological
responses including (i) inducing the synthesis of
15 various thermogenic enzymes which are effective for
regulating metabolism and thereby promoting weight
control without affecting caloric intake, and (ii)
inducing an increase in the production of the sex
hormones androgen and estrogen.

20 The ability of DHEA to promote weight
control is believed to be mediated through enhanced
thermogenesis (conversion of foodstuffs to heat
energy rather than chemical energy such as ATP
and/or triacylglycerides). The thermogenic effect
25 mediated by DHEA is believed to result from the
ability of DHEA to stimulate the synthesis of
thermogenic enzymes including mitochondrial glycerol

- 2 -

3-phosphate dehydrogenase (G3P-DH) and cytosolic malic enzyme (ME). Such enzymes tend to reduce the efficiency of energy metabolism within the body.

Unfortunately, DHEA is generally
5 considered to be ineffective as a weight controlling therapeutic agent because the dosage necessary to achieve weight control frequently produces significant adverse side-effects including substantial increases in the concentration of sex
10 hormones.

Accordingly, a therapeutic agent possessing the weight control characteristic of DHEA without the adverse side-effect of stimulating the synthesis of sex hormones would be extremely useful.
15 In addition, the effectiveness of such a therapeutic agent could be significantly enhanced if the agent possessed an increased weight control activity relative to DHEA.

Summary of the Invention

20 A method for promoting weight maintenance and/or weight loss (hereinafter referenced collectively as "weight control") which includes the step of treating a subject with an effective weight controlling amount of a $\Delta 5$ -androsterone which is
25 effective for stimulating the desired biological

- 3 -

response of promoting weight control while being substantially ineffective for inducing the undesired biological response of synthesising sex hormones.

5 Δ 5-androstenes providing the desired beneficial biological response without the undesired biological response include:

- | | | |
|----|--|------|
| | Δ 5-Androstene-3 β ,7 α -diol-17-one | (1) |
| | Δ 5-Androstene-3 β -ol-7,17-dione | (2) |
| | Δ 5-Androstene-3 β ,7 α ,17 β -triol | (3) |
| 10 | Δ 5-Androstene-3 β ,17 β -diol-7-one | (4) |
| | Δ 5-Androstene-3 β -acetoxy-7,16,17-trione | (5) |
| | Δ 5-Androstene-3 β ,16 α -dihydroxy-7,17-dione | (6) |
| | Δ 5-Androstene-3 β -propionoxy-16 β -acetoxy-7,17-dione | (7) |
| 15 | Δ 5-Androstene-3 β ,7 α ,17 β -triol-16-one | (8) |
| | Δ 5-Androstene-3 β ,17 β -diol-7,16-dione | (9) |
| | Δ 5-Androstene-3 β ,16 α ,17 β -triol,7-one | (10) |

and derivatives thereof wherein one or more of the hydroxyl or keto substituents is a group convertible thereto by hydrolysis.

20 Examples of such hydrolyzable groups include hydroxyl groups esterified with an acid selected from the group consisting of (i) normal or branched, saturated or unsaturated C₂₋₂₂ aliphatic acids, (ii) C₇₋₁₂ aromatic acids, (iii) C₃ or larger dicarboxylic acids in which only one of the carboxyl groups is esterified to the hydroxyl group(s) on the steroid, or (iv) inorganic acids such as sulfuric and phosphoric.

- 4 -

**Detailed Description of the Invention
Including a Best Mode**

The $\Delta 5$ -androstenes identified below possess a unique combination of properties including the ability to promote weight control without affecting appetite and without stimulating the production of sex hormones.

	$\Delta 5$ -Androstene- $3\beta, 7\alpha$ -diol-17-one	(1)
	$\Delta 5$ -Androstene- 3β -ol-7,17-dione	(2)
10	$\Delta 5$ -Androstene- $3\beta, 7\alpha, 17\beta$ -triol	(3)
	$\Delta 5$ -Androstene- $3\beta, 17\beta$ -diol-7-one	(4)
	$\Delta 5$ -Androstene- 3β -acetoxy-7,16,17-trione	(5)
	$\Delta 5$ -Androstene- $3\beta, 16\alpha$ -dihydroxy-7,17-dione	(6)
15	$\Delta 5$ -Androstene- 3β -propionoxy-16 β -acetoxy-7,17-dione	(7)
	$\Delta 5$ -Androstene- $3\beta, 7\alpha, 17\beta$ -triol-16-one	(8)
	$\Delta 5$ -Androstene- $3\beta, 17\beta$ -diol-7,16-dione	(9)
	$\Delta 5$ -Androstene- $3\beta, 16\alpha, 17\beta$ -triol,7-one	(10)

and derivatives thereof wherein one or more of the hydroxyl or keto substituents is a group convertible thereto by hydrolysis.

Examples of such hydrolyzable groups include hydroxyl groups esterified with an acid selected from the group consisting of (i) normal or branched, saturated or unsaturated C_{2-22} aliphatic acids, (ii) C_{7-12} aromatic acids, (iii) C_3 or larger dicarboxylic acids in which only one of the carboxyl groups is esterified to the hydroxyl group(s) on the steroid, and (iv) inorganic acids such as sulfuric and phosphoric.

These steroids may also be administered as a carbamate or other such derivative capable of

- 5 -

releasing the specified steroid within the intestinal tract, blood and/or body tissue. The desired biological activity is a function of the steroid moiety. Derivations of a moiety may serve a variety of beneficial functions including stabilization of the steroid, flavoring or obscuring the natural flavor of the steroid, or affecting the rate of absorption of the steroid.

Synthesis

- 10 (1) Δ^5 -Androstene- 3β , 7α -diol-17-one
(7α -hydroxy DHEA)

Δ^5 -Androstene- 3β , 7α -diol-17-one (7α -hydroxy DHEA) can be synthesized from commercially available DHEA acetate by sequentially synthesizing:

- 15 Δ^5 -androstene- 3β hydroxy-17-one acetate (DHEA acetate)
 Δ^5 -androstene- 3β -hydroxy-7-bromo-17-one acetate
(7-Br DHEA acetate)

- 20 Δ^5 -androstene- 3β , 7α -dihydroxy-17-one diacetate (7-OH DHEA diacetate)

Δ^5 -androstene- 3β , 7α -dihydroxy-17-one (7-hydroxy DHEA)

- 25 Δ^5 -Androstene- 3β -hydroxy-7-bromo-17-one acetate (7-bromo DHEA acetate) can be synthesized from Δ^5 -androstene- 3β -hydroxy-17-one acetate (DHEA acetate) by reacting DHEA acetate with a brominating

- 6 -

agent, such as dibromantin (1,3-dibromo-5,5-dimethylhydantoin) or N-bromosuccinimide. The 7-bromo DHEA acetate is unstable and must be used immediately in the next step of the process.

5 The 7-bromo DHEA acetate contains an isomeric mixture of 7 α -bromo and 7 β -bromo. The isomeric mixture, may be equilibrated to 7 α -bromo DHEA acetate in accordance with the method described for equilibrating a cholesterol derivative in
10 Confalone, P.N., Kulesha, I.D., and Uskokovic, M.R. Jour. Org. Chem., vol. 46, pp 1030-1032 (1981). Briefly, the isomeric mixture of 7-bromo DHEA acetate is contacted with cold anhydrous LiBr and shielded from light to convert the product from an
15 isomeric mixture of 7 α and 7 β to predominantly 7 α .

Δ^5 -Androstene-3 β ,7 α -dihydroxy-17-one diacetate (7-hydroxy DHEA diacetate) may be synthesized from 7-bromo DHEA acetate by reacting the 7-bromo DHEA acetate with a mixture of glacial
20 acetic acid and powdered silver acetate at room temperature in a suitable solvent, such as a mixture of methylene chloride and acetone.

Δ^5 -Androstene-3 β ,7 α -dihydroxy-17-one (7-hydroxy DHEA) may be synthesized from 7-hydroxy DHEA diacetate by dissolving the 7-hydroxy DHEA diacetate
25 in methanol and reacting the dissolved 7-hydroxy

- 7 -

DHEA diacetate with an aqueous solution containing a suitable base such as Na_2CO_3 .

The synthesized 7-hydroxy DHEA may then be purified by (i) evaporating the methanol in vacuo, (ii) extracting the 7-hydroxy DHEA into an appropriate organic solvent such as dichloromethane, (iii) evaporating the organic solvent in vacuo, (iv) azeotropically drying the extracted solids containing the 7-hydroxy DHEA with a suitable organic solvent such as ethanol, (v) dissolving the extracted solids in acetone, and then (vi) adding hexane to the acetone solution to produce purified crystals of Δ^5 -androstene- $3\beta,7\alpha$ -diol-17-one (7-hydroxy DHEA).

A second crop of Δ^5 -androstene- $3\beta,7\alpha$ -diol-17-one (7 α -hydroxy DHEA) crystals may be obtained by cooling the resultant solution below room temperature.

(2) Δ^5 -Androstene- 3β -ol-7,17-dione
(7-keto DHEA)

Δ^5 -Androstene- 3β -ol-7,17-dione (7-keto DHEA) can be synthesized from commercially available DHEA acetate by sequentially synthesizing:

3β -acetoxy- Δ^5 -androstene-17-one (DHEA acetate)
 3β -acetoxy- Δ^5 -androstene-7,17 dione (7-one DHEA acetate)
 Δ^5 -androstene- 3β -hydroxy-7,17-dione (7-one DHEA)

- 8 -

3 β -Acetoxy- Δ 5-androstene-7,17-dione (7-one DHEA acetate) can be synthesized from 3 β -acetoxy- Δ 5-androstene-17-one (DHEA acetate) by reacting the DHEA acetate with the oxidizing agent CrO₃ in accordance with the procedure outlined in Fieser, L.F., Jour. Am. Chem. Soc., vol 75, pp 4386-4394 (1953).

Δ 5-Androstene-3 β -hydroxy-7,17-dione (7-one DHEA) can be synthesized from the 7-one DHEA acetate and purified by employing the deesterification and purification steps set forth above in connection with the synthesis and purification of 7-hydroxy DHEA.

(3) Δ 5-Androstene-3 β ,7 α ,17 β -triol
(7 α -hydroxy-androstenediol)

Δ 5-Androstene-3 β ,7 α ,17 β -triol (3) can be synthesized from commercially available androstenediol-diacetate by sequentially synthesizing:

Δ 5-androstene-3 β ,17 β -diol-diacetate (20)
 Δ 5-androstene-3 β ,17 β -diol-7-bromo-diacetate (21)
 Δ 5-androstene-3 β ,7 α ,17 β -triol-3,7,17-triacetate (22)
 Δ 5-androstene-3 β ,7 α ,17 β -triol (3)

Δ 5-Androstene 3 β ,17 β -diol-7-bromo-diacetate (21) can be synthesized from the commercially available Δ 5-androstene-3 β ,17 β -diol-diacetate (20) by reacting (20) with a brominating

- 9 -

agent, such as Dibromantin (1,3-dibromo-5,5-dimethylhydantoin) or N-bromosuccinimide. The synthesized 7-bromo-androstenediol diacetate (21) is unstable and must be used immediately.

5 The 7-bromo-androstenediol diacetate (21) contains an isomeric mixture of 7 α -bromo-androstenediol diacetate (21a) and 7 β -bromo-androstenediol diacetate (21b) which can be equilibrated to a 7 α -bromo-androstenediol (21a) in
10 accordance with the method described in Confalone, P.N. Kulesha, I.D., and Uskokovic, M.R. Jour. Org. Chem., vol. 46, pp 1030-1032 (1981). Briefly, the isomeric mixture of 7-bromo-androstenediol diacetate (21a & 21b) is contacted with anhydrous LiBr and
15 shielded from light to convert the product from an isomeric mixture of 7 α and 7 β to predominantly 7 α .

Δ^5 -Androstene-3 β ,7 α ,17 β -triol-3,7,17-triacetate (22) may be synthesized from the 7 α -bromo-androstenediol diacetate (21a) by reacting
20 (21a) with a mixture of glacial acetic acid and silver acetate in a suitable solvent, such as a mixture of methylene chloride and acetone.

Δ^5 -Androstene-3 β ,7 α ,17 β -triol (3) may be synthesized from the 7 α -hydroxy-androstenediol triacetate (22) by reacting the 7 α -hydroxy-androstenediol triacetate (22) in methanol with an
25

- 10 -

aqueous solution containing a suitable base such as Na_2CO_3 .

The synthesized 7α -hydroxy-androstenediol (3) may then be purified by (i) evaporating the methanol in vacuo, (ii) extracting the 7α -hydroxy-androstenediol (3) into an appropriate organic solvent such as dichloromethane, (iii) evaporating the organic solvent in vacuo, (iv) azeotropically drying the extracted solids containing the 7α -hydroxy-androstenediol (3) with a suitable organic solvent such as ethanol, (v) dissolving the extracted solids in acetone, and then (vi) adding hexane to the acetone solution to produce purified crystals of Δ^5 -androstene- $3\beta,7\alpha,17\beta$ -triol (7α -hydroxy-androstenediol) (3).

A second crop of Δ^5 -androstene- $3\beta,7\alpha,17\beta$ -triol (3) crystals may be obtained by cooling the resultant solution below room temperature.

(4) Δ^5 -Androstene- $3\beta,17\beta$ -diol-7-one
(7-keto-androstenediol)

Δ^5 -Androstene- $3\beta,17\beta$ -diol-7-one (4) can be synthesized from commercially available androstenediol-diacetate by sequentially synthesizing:

Δ^5 -androstene- $3\beta,17\beta$ -diol-7-one-diacetate (41)
 Δ^5 -androstene- $3\beta,17\beta$ -diol-7-one (4)

- 11 -

Δ^5 -Androstene- 3β , 17β -diol-7-one-diacetate (41) can be synthesized from Δ^5 -androstene- 3β , 17β -diol-diacetate (androstenediol-diacetate) (40) by reacting the androstenediol-diacetate (40) with the oxidizing agent CrO_3 in accordance with the procedure outlined in Fieser, L.F. Jour. Am. Chem. Soc., vol. 75, pp 4386-4394 (1953).

Δ^5 -Androstene- 3β , 17β -diol-7-one (7-keto-androstenediol) (4) can be synthesized from Δ^5 -androstene- 3β , 17β -diol-7-one-diacetate (41) and purified by employing the deesterification and purification steps set forth above with respect to the synthesis and purification of 7α -hydroxy DHEA (1) from 7α -hydroxy DHEA diacetate.

(5) Δ^5 -Androstene- 3β -acetoxy-7,16,17-trione

Δ^5 -Androstene- 3β -acetoxy-7,16,17-trione (5) may be synthesized from commercially available DHEA acetate by sequentially converting:

3β -acetoxy- Δ^5 -androstene-17-one (DHEA-acetate)

-to-

3β -acetoxy- Δ^5 -androstene-7,17-dione (51)

- to -

3β -acetoxy-17-hydroxy- Δ^5 ,
 Δ^{16} -androstadiene-7-one-
trimethylsilyl ether
(52a)

30%

3β -trimethylsilylacetoxy-
17-hydroxy- Δ^5 , Δ^{16} -
androstadiene-7-one
trimethylsilyl ether
(52b)

70%

- 12 -

- to -

5 3β -acetoxy-16-phenylseleno- Δ^5 -androstene-7,17-dione (53a)

3β -trimethylsilylacetoxy-16-phenylseleno- Δ^5 -androstene-7,17-dione (53b)

- to -

10 3β -acetoxy-16-phenylseleno- Δ^5 -androstene-7,17-dione (53a)

- to -

15 3β -acetoxy- Δ^5 -androstene-16-phenylseleno-7,17-dione (54)

3β , acetoxy- Δ^5 -androstene-16-phenylseleno-16-m-chlorobenzoate-7,17-dione (55)

- to -

20 3β -acetoxy-16-m-chlorobenzoate- Δ^5 , Δ^{15} -androstadiene-7,17-dione (56)

3β , 16-diacetoxy- Δ^5 , Δ^{15} -androstadiene-7,17-dione (57)

- to -

3β -acetoxy- Δ^5 -androstene-7,16,17-trione (5)

3β -Acetoxy- Δ^5 -androstene-7,17-dione (51)

25 can be synthesized from 3β -acetoxy- Δ^5 -androstene-17-one (DHEA-acetate) by reacting DHEA-acetate with the oxidizing agent CrO_3 in accordance with the procedure outlined in Fieser, L.F., Jour. Am. Chem. Soc., vol. 75, pp 4386-4394 (1953).

30 A mixture of 70% 3β -(trimethylsilyl)acetoxy-17-hydroxy- Δ^5 , Δ^{16} -androstadiene-7-one trimethylsilyl

- 13 -

androstadiene-7-one trimethylsilyl ether (52a) may be synthesized from the 3 β -acetoxy- Δ 5-androstene 7,17-dione (51) by reacting (51) with lithium diisopropyl amide in the presence of
5 trimethylchlorosilane in a suitable solvent such as tetrahydrofuran at -78°C.

3 β -Acetoxy-16-phenylseleno- Δ 5-androstene-7,17-dione (53a) and 3 β -(trimethylsilyl)acetoxy-16-phenylseleno- Δ 5-androstene-7,17-dione (53b) may be
10 synthesized from 3 β -acetoxy-17-hydroxy- Δ 5, Δ 16-androstadiene-7-one trimethylsilyl ether (52a) and 3 β -(trimethylsilyl)acetoxy-17-hydroxy- Δ 5, Δ 16-androstadiene-7-one trimethylsilyl ether (52b) respectively by reacting the mixture of (52a) and
15 (52b) with benzeneselenenyl chloride in the presence of pyridine and a suitable solvent such as tetrahydrofuran at -78°C.

The carbon silylated acetate attached to the C₃ carbon atom on the (53b) fraction of the (53) mixture may be desilylated so as to convert (53b) to
20 (53a) within the (53) mixture by treating the (53) mixture with tetra-n-butylammonium fluoride in a suitable solvent system such as ether-dichloromethane-tetrahydrofuran-water.

3 β ,16-Diacetoxy- Δ 5-androstene-16-phenylseleno-7,17-dione (54) may be synthesized from
25

- 14 -

the 3 β -acetoxy-16-phenylseleno- Δ 5-androstene-7,17-dione (53a) by submitting (53a) to the seleno-Pummerer reaction outlined in Ikota, N.; Ganem, B. Jour. Org. Chem., vol. 43, pp. 1607-1608 (1978).

5 Briefly, the 3 β -acetoxy-16-phenylseleno- Δ 5-androstene-7,17-dione (53a) is sequentially reacted with m-chloroperbenzoic acid and acetic anhydride in a suitable solvent. 3 β -acetoxy- Δ 5-androstene-16-phenylseleno-16-m-chlorobenzoate-7,17-dione (55) is
10 also synthesized during this reaction.

3 β ,16-diacetoxy- Δ 5, Δ 15-androstadiene-7,17-dione (57) may be synthesized from 3 β ,16-diacetoxy- Δ 5-androstene-16-phenylseleno-7,17-dione (55) by
15 oxidative dehydrogenation. The 3 β -acetoxy- Δ 5-androstene-16-phenylseleno-16-m-chlorobenzoate-7,17-dione (54) present with (55) produces 3 β -acetoxy-16-m-chlorobenzoate- Δ 5, Δ 15-androstadiene-7,17-dione (56) which may be separated by chromatography if
desired.

20 3 β -acetoxy- Δ 5-androstene-7,16,17-trione (5) may be synthesized from the 3 β -acetoxy- Δ 5, Δ 15-androstadiene-16-m-chlorobenzoate-7,17-dione (56) and/or 3 β ,16-diacetoxy- Δ 5, Δ 15-androstadiene-7,17-dione (57) by treating them with triethylamine in
25 methanol.

- 15 -

(6) Δ^5 -Androstene- 3β , 16α -dihydroxy-7,17-dione
(7-keto- 16α -hydroxy DHEA)

5 3β , 16α -dihydroxy- Δ^5 -androstene-7,17-dione can
be synthesized by the following sequence from DHEA
propionate. DHEA propionate can be made by simple
esterification of DHEA.

3β -propionoxy- Δ^5 -androstene-17 one (DHEA-
propionate)

-to-

10 3β -propionoxy- Δ^5 -androstene-7,17-dione (61)

- to -

3β -propionoxy-17-hydroxy- Δ^5 , Δ^{16} -androstadiene-
7-one trimethylsilyl ether (62)

- to -

15 3β -propionoxy- 16α -hydroxy- Δ^5 -
androstene-7,17-dione (63)

- to -

3β , 16α -dihydroxy- Δ^5 -
androstene-7,17-dione (6)

20 3β -Propionoxy- Δ^5 -androstene-7,17-dione

(61) (NMR set forth at table eight) can be
synthesized from 3β -propionoxy- Δ^5 -androstene-17-one
(DHEA-propionate) by reacting the DHEA-propionate
with the oxidizing agent CrO_3 in accordance with the
25 procedure outlined in Fieser, L.F., Jour. Am. Chem.
Soc., vol. 75, pp 4386-4394 (1953).

3β -Propionoxy-17-hydroxy- Δ^5 , Δ^{16} -
androstadiene-7-one trimethylsilyl ether (62) may be

- 16 -

synthesized from the 3 β -propionoxy- Δ 5-androstene-7,17-dione (61) by reacting (61) with lithium diisopropyl amide in the presence of trimethylchlorosilane in a suitable solvent such as tetrahydrofuran at -78°C.

3 β -Propionoxy-16 α -hydroxy- Δ 5-androstene-7,17-dione (63) may be synthesized from the 3 β -propionoxy-17-hydroxy- Δ 5, Δ 16-androstadiene-7-one trimethylsilyl ether (62) by oxidation with m-chloroperbenzoic acid in tetrahydrofuran followed by treatment with a 1N HCl solution.

The final desired product 3 β ,16 α -dihydroxy- Δ 5-androstene-7,17-dione (6) may then be synthesized from the 3 β -propionoxy-16 α -hydroxy- Δ 5-androstene-7,17-dione (63) by treatment with sulfuric acid in methanol.

(7) Δ 5-Androstene-3 β -propionoxy,16 β -acetoxy-7,17-dione
(7-Keto-16 β -acetoxy DHEA propionate)

Δ 5-Androstene-3 β -propionoxy-16 β -acetoxy-7,17-dione (7) can be synthesized from Δ 5-androstene-3 β -propionoxy-16 α -hydroxy-7,17-dione (63) produced in accordance with the reaction sequence set forth above. The Δ 5-androstene-3 β -propionoxy-16 α -hydroxy-7,17-dione is treated in accordance with the Mitsunobu conditions set forth in Hughes, D. L.; Reamer, R.A.; Bergan, J.J.; Grabowski, E.J.J. Jour

- 17 -

Am. Chem. Soc., vol. 110, pp 6487-6491 to invert the configuration and acetylate the 16 hydroxy group.

(8) Δ^5 -Androstene- $3\beta,7\alpha,17\beta$ -triol-16-one

Δ^5 -Androstene- $3\beta,7\alpha,17\beta$ -triol-16-one (8) can be synthesized from Δ^5 -androstene- $3\beta,16\alpha$ -dihydroxy-17-one diacetate (81). The Δ^5 -androstene- $3\beta,16\alpha$ -dihydroxy-17-one diacetate (81) starting material can be synthesized in accordance with the procedure set forth in Numazawa, M. and Osawa, Y. Steroids, vol. 32, p 519 (1978).

Δ^5 -Androstene- $3\beta,16\alpha$ -diacetoxo-7-bromo-17-one (82) can be synthesized from the Δ^5 -androstene- $3\beta,16\alpha$ -diacetoxo-17-one (81) by reacting Δ^5 -androstene- $3\beta,16\alpha$ -diacetoxo-17-one (81) with a brominating agent, such as Dibromantin (1,3-dibromo-5,5-dimethylhydantoin). The Δ^5 -androstene- $3\beta,16\alpha$ -diacetoxo-7-bromo-17-one (82) is unstable and must be used immediately in the next step of the process.

The Δ^5 -androstene- $3\beta,16\alpha$ -diacetoxo-7-bromo-17-one (82) contains an isomeric mixture of 7α -bromo and 7β -bromo isomers. The isomeric mixture, may be equilibrated to 7α -bromo in accordance with the method described for equilibrating a cholesterol derivative in Confalone, P.N., Kulesha, I.D., and Uskokovic, M.R. Jour. Org. Chem., vol. 46, pp 1030-1032 (1981). Briefly, the isomeric mixture is contacted with cold

- 18 -

anhydrous LiBr and shielded from light to convert the product from an isomeric mixture of 7α and 7β to predominantly 7α .

5 Δ^5 -Androstene- 3β , 16α -diacetoxo- 7α -hydroxy-17-one (83) may be synthesized from the Δ^5 -androstene- 3β , 16α -diacetoxo- 7α -bromo-17-one (82) by reacting the Δ^5 -androstene- 3β , 16α -diacetoxo- 7α -bromo-17-one (82) with a mixture of glacial acetic acid and powdered silver acetate at room temperature
10 in a suitable solvent, such as a mixture of methylene chloride and acetone. Also produced in this reaction is a 20% yield of Δ^5 -androstene- 3β , 7α , 16α -triacetoxo-17-one.

Δ^5 -Androstene- 3β , 7α , 17β -trihydroxy-16-one
15 (8) can be synthesized from the Δ^5 -Androstene- 3β , 16α -diacetoxo- 7α -hydroxy-17-one (83) by dissolving the Δ^5 -Androstene- 3β , 16α -diacetoxo- 7α -hydroxy-17-one (83) in a room temperature methanol solution of K_2CO_3 and stirring the solution for two
20 hours. The alkaline solution enolizes the 17-keto to form the more stable 17-hydroxy-16-one combination. The Δ^5 -androstene- 3β , 7α , 17 -trihydroxy-16-one (8) may then be isolated by filtering to remove the insoluble salt, evaporating the methanol
25 in vacuo, purifying and remove extracting the compound by chromatography. The steroid crystallizes from a hot methanol/ether solution upon cooling.

- 19 -

(9) Δ^5 -Androstene- $3\beta,17\beta$ -diol-7,16-dione

Δ^5 -Androstene- $3\beta,17\beta$,-diol-7,16-dione (9) can be synthesized from 3β -propionoxy- 16α -hydroxy- Δ^5 -androstene-7,17-dione (63) by treating 3β -
5 propionoxy- 16α -hydroxy- Δ^5 -androstene-7,17-dione (63) with a 5% aqueous sodium carbonate solution in methanol.

(10) Δ^5 -Androstene- $3\beta,16\alpha,17\beta$ -triol,7-one

Δ^5 -Androstene- $3\beta,16\alpha,17\beta$ -triol-7-one (10) can
10 be synthesized from $3\beta,16\alpha,17\beta$ -triacetoxy- Δ^5 -androstene by reacting the $3\beta,16\alpha,17\beta$ -triacetoxy- Δ^5 -androstene with the oxidizing agent CrO_3 in accordance with the procedure outlined in Fieser,
L.F., Jour. Am. Chem. Soc., vol 75, pp 4386-4394
15 (1953) with subsequent hydrolysis of the acetyl groups.

Without intending to be unduly limited thereby, it is believed that the steroids identified above may be modified without loss of biological activity
20 by esterifying one or more of the hydroxyl groups with any of a variety of organic acids and inorganic acids such as sulfuric or phosphoric acid.

Treatment

A subject may be treated with the steroids
25 specified herein by any of the commonly accepted

- 20 -

practices including orally or by injection. While many factors affect the dose rate required to attain the desired biological response, treatment at a dosage rate of about 0.1 to 2 grams, preferably about 0.5 to 2 grams, of the steroid per 100 kilograms body weight per day should generally be effective for promoting weight control. A dose rate of less than 0.1 gram per 100 kilograms bodyweight per day is generally ineffective for preventing weight gain while a dose rate of greater than about 2 grams per 100 kilograms bodyweight per day increases the cost of treatment without providing a corresponding benefit in performance. The optimum dose rate to be administered to a subject is case specific as the optimum dose rate depends upon several factors including current body composition (percent fat), the desired effect (weight gain maintenance versus weight loss), eating habits of the individual (daily caloric intake), and the like. As would be expected, the dose rate provided to a subject for the purpose of promoting weight loss will be greater than that necessary to promote weight maintenance assuming identical caloric intake under each program.

Without intending to be limited thereby, we believe that the steroids specified herein are metabolic intermediates along the pathway to conversion of DHEA to an ultimate metabolite(s)

- 21 -

which is actually responsible for mediating an enhanced production of thermogenic enzymes such as glycerol 3-phosphate dehydrogenase and malic enzyme.

5 A subject may be treated with one of the steroids specified herein on substantially any time schedule. It is believed that the steroids specified herein are effective for promoting weight control while the steroid itself is actively present within the body as well as while the increased
10 concentration of thermogenic enzyme(s) induced by the steroid remain elevated. The in vivo life expectancy of the steroids and the thermogenic enzyme(s) induced thereby is not yet fully known. However, it is believed that the steroids themselves
15 are not stored within the body and are removed and/or deactivated within days after administration. Accordingly, for optimum effectiveness, the subject under treatment should be treated every day or two. For reasons of convenience the subject under
20 treatment may be treated less frequently, such as once a week, when less than maximum performance is acceptable.

As is apparent from the factors which affect dosage and dose rate, each particular subject
25 should be carefully and frequently reviewed and the dosage and/or dose rate altered in accordance with the particular situation.

- 22 -

Experimental**Example I**
(Steroid 1)Synthesis5 Δ^5 -Androstene- 3β , 7α -diol-17-one

(Step 1) Into a two liter, triple neck, round bottom flask equipped with a magnetic stirrer and a reflux condenser was placed 1000 ml hexane (b.p 69-71°), 10 grams (0.03 mmoles) DHEA acetate and 13.6 grams (0.16 moles) NaHCO₃ to form a first mixture. The first mixture was placed under a N₂ atmosphere and heated under constant agitation to reflux. Into the refluxing first mixture was added 6.11 grams (0.021 moles) Dibromantin (1,3-dibromo-5,5-dimethylhydantoin) as a brominating agent to form a second mixture. The second mixture gradually turned orange after which it rapidly turned a pale white/yellow. The second mixture was refluxed for 30 minutes, cooled to room temperature and filtered through a sintered glass funnel. The residue was rinsed with 50 ml dichloromethane and the combined filtrate rotovapped to dryness at a temperature of less than 35°C. The residue (Δ^5 -androstene- 3β -ol-7-bromo-17-one) is unstable to storage and was used immediately in step two.

(Step 2) The residue was resolubilized in 80 ml of dichloromethane in a one liter stoppered flask equipped with a magnetic stirrer and placed in an ice bath. Into the resolubilized filtrate was

- 23 -

added 8 grams anhydrous LiBr in 320 ml ice-cold acetone to form a third mixture. The third mixture was shielded from light and stirred continuously for three hours. The resulting mixture containing

5 predominantly Δ^5 -androstene- 3β -ol- 7α -bromo-17-one was allowed to warm to room temperature and used immediately in step three.

(Step 3) Into a 500 ml flask equipped with a magnetic stirrer was placed 320 ml

10 dichloromethane, 80 ml glacial acetic acid, and 26 grams of silver acetate to form a first suspension. The first suspension was stirred continuously for 20 minutes at room temperature. The stirred first suspension was added under constant agitation into

15 the third mixture of predominantly Δ^5 -androstene- 3β -ol- 7α -bromo-17-one to form a second suspension. The second suspension was constantly stirred for 30 minutes at room temperature after which the suspension was filtered through a sintered glass

20 funnel to separate a solid residue. The filtered solid residue was rinsed with 100 ml dichloromethane. The filtrate was washed three times with 1000 ml of water, once with 1000 ml of a 5% NaHCO_3 solution, and then twice more with water.

25 The organic mixture containing Δ^5 -androstene- 3β -17 α -diol-17-one diacetate was then rotovapped to dryness.

- 24 -

(Step 4) The dried extracted solids were resolubilized in 500 ml methanol in a one liter, triple necked flask equipped with a magnetic stirrer and a reflux condenser to form a fourth mixture.

5 The fourth mixture was placed under a N_2 atmosphere and heated under constant stirring to reflux. Into the fourth mixture was added 250 ml of a 5% aqueous solution of Na_2CO_3 to form a fifth mixture. The fifth mixture was refluxed under constant agitation

10 for 45 minutes. The methanol was rotovapped off and the aqueous fifth mixture carefully brought to a pH of 7 with an appropriate amount of glacial acetic acid. The neutralized fifth mixture was extracted twice with 100 ml of dichloromethane. The

15 dichloromethane solution of Δ^5 -androstene- $3\beta,7\alpha$ -diol-17-one was rotovapped to near dryness, azeotropically dried with absolute ethanol, and then azeotropically dried twice with acetone. Warm acetone was added to the dried extracted solids

20 until the solids were completely dissolved to form a sixth mixture. Hexane was added to the sixth mixture until the mixture began to cloud at which time crystals of Δ^5 -androstene- $3\beta,7\alpha$ -diol-17-one began to form at room temperature.

25 A second crop of Δ^5 -androstene- $3\beta,7\alpha$ -diol-17-one crystals was obtained by cooling the remaining sixth mixture.

- 25 -

The crystals melt at 187-189°C. When recrystallized from acetone/hexane they melt at 192-193°C.

5 **Example II**
 (Steroid 1)

Synthesis
 Δ 5-Androstene-3 β -7($\alpha\beta$)-diol-17-one

Δ 5-Androstene-3 β -7($\alpha\beta$)-diol-17-one was
manufactured in accordance with the procedure set
10 forth in Example I except that Step 2 was eliminated
with the dried filtrate from Step 1 simply
resolubilized in the 80 ml of dichloromethane in
preparation for Step 3.

15 **Example III**
 (Steroid 2)

Synthesis
 Δ 5-Androstene-3 β -ol-7,17-dione

 (Step 1) Into a 50 ml flask equipped with
a magnetic stirrer and a water bath was placed 6.5
20 ml acetic anhydride, 23 ml acetic acid, 1.7 grams
sodium acetate, and 2 grams DHEA acetate to form a
first mixture. Into the first mixture was added 2
grams chromium trioxide over a thirty minute period
to form a second mixture. The first mixture was
25 maintained at a constant temperature of 56-58°C and
continuously agitated during addition of the
chromium trioxide. The second mixture was

- 26 -

maintained at 56-58°C and continuously agitated for an additional hour after which the second mixture was cooled and slowly poured under continuous agitation into 600 ml of ice water to form a precipitate. The flocculent precipitate was collected on a sintered glass funnel and washed with water until no longer green. After drying in vacuo over P₂O₅, the product was dissolved in hot methanol and crystallized to yield substantially pure Δ⁵-androstene-3β-acetoxy-7,17-dione having a melting point of 184-185°C.

(Step 2) The precipitate was resolubilized in 500 ml of methanol in a one liter, triple necked, round bottom flask equipped with a magnetic stirrer and reflux condenser to form a third mixture. The third mixture was placed under a N₂ atmosphere and heated under constant agitation to reflux. Into the third mixture was added 250 ml of a 5% solution of Na₂CO₃ to form a fourth mixture. The fourth mixture was refluxed under constant agitation for 45 minutes. The methanol was rotovapped off and the aqueous fourth mixture carefully brought to a pH of 7 with an appropriate amount of glacial acetic acid. The neutralized fourth mixture was extracted with two 100 ml portions of dichloromethane, the two dichloromethane portions combined, and the dichloromethane evaporated in vacuo. The extracted solids were then

- 27 -

azeotropically dried first with absolute ethanol and then with two separate portions of acetone.

Methanol was added to the dried extracted solids until the solids were completely dissolved to form a fifth mixture. Hexane was added to the fifth mixture until the mixture began to cloud at which time crystals of Δ^5 -androstene- 3β -ol-7,17 dione formed at room temperature.

A second crop of Δ^5 -androstene- 3β -ol-7,17-dione crystals was obtained by cooling the remaining sixth mixture.

The resultant product had a melting point of 235-238°C.

Example IV
(Steroid 3)

Synthesis
 Δ^5 -Androstene- 3β , 7α , 17β -triol

(Step 1) Into a two liter round bottom flask equipped with a magnetic stirrer and a reflux condenser was placed 1000 ml hexane (b.p 69-71°), 10 grams (0.03 moles) Δ^5 -androstene- 3β - 17β -diol diacetate and 13.6 grams (0.16 moles) NaHCO_3 to form a first mixture. The first mixture was placed under a N_2 atmosphere and heated under constant agitation to reflux. Into the refluxing first mixture was added 6.11 g (0.021 moles) Dibromantin (1,3-dibromo-5,5-dimethylhydantoin) as a brominating agent to form a second mixture. The second mixture gradually

- 28 -

turned orange after which it rapidly turned a pale white/light yellow. The second mixture was refluxed for 30 minutes, cooled to room temperature, and filtered through a sintered glass funnel. The residue was rinsed with 50 ml dichloromethane and rotovapped to dryness at a temperature of less than 35°C. The dry filtrate (Δ^5 -androstene-3 β -17 β -diol-7-bromide) is unstable to storage and was used immediately in step two.

(Step 2) The dried filtrate was resolubilized in 80 ml of dichloromethane in a flask equipped with a magnetic stirrer and placed in an ice bath. Into the resolubilized filtrate was added 8 grams anhydrous LiBr in 320 ml ice-cold acetone to form a third mixture. The third mixture was shielded from light and stirred continuously for three hours. The resulting mixture of predominantly Δ^5 -androstene-3 β -17 β -diol-7 α -bromide was allowed to warm to room temperature and used immediately.

(Step 3) Into a 500 ml flask equipped with a magnetic stirrer was placed 320 ml methylene chloride, 80 ml glacial acetic acid, and 26 grams silver acetate to form a first suspension. The first suspension was stirred continuously for 20 minutes at room temperature. The stirred first suspension was added under constant agitation to the third mixture of predominantly Δ^5 -androstene-3 β -17 β -diol-7 α -bromide to form a second suspension. The

- 29 -

second suspension was constantly stirred for 30 minutes at room temperature during which the suspension gradually darkened and was then filtered through a sintered glass funnel. The residual solids retained on the glass filter were rinsed with 10 ml dichloromethane. The filtrate was washed three times with 1000 ml of water, neutralized with 1000 ml of a 5% NaHCO₃ solution, and then washed twice more with water. The resulting organic mixture containing Δ^5 -androstene-3 β ,7 α ,17 β -triol-3,17-diacetate was then rotovapped to dryness.

(Step 4) The dried extracted solids were resolubilized in 500 ml methanol within in a one liter, triple necked, round bottom flask equipped with a magnetic stirrer and a reflux condenser to form a fourth mixture. The fourth mixture was placed under a N₂ atmosphere and heated under constant agitation to reflux. Into the fourth mixture was added 250 ml of a 5% aqueous solution of Na₂CO₃ to form a fifth mixture. The fifth mixture was refluxed under constant agitation for 45 minutes. The methanol was rotovapped off and the aqueous fifth mixture carefully brought to a pH of 7 with an appropriate amount of glacial acetic acid. The neutralized fifth mixture was extracted twice with 100 ml dichloromethane and the combined extract evaporated in vacuo. The extracted solids (Δ^5 -androstene-3 β ,7 α ,17 β -triol) were azeotropically

- 30 -

dried with absolute ethanol and then twice with acetone. Warm acetone was added to the dried extracted solids until the solids were completely dissolved to form a sixth mixture. Hexane was added to the sixth mixture until the mixture began to cloud, at which time crystals of Δ^5 -androstene- $3\beta,7\alpha,17\beta$ -triol formed at room temperature.

A second crop of Δ^5 -androstene- $3\beta,7\alpha,17\beta$ -triol crystals was obtained by cooling the remaining sixth mixture.

- 31 -

Example V
(Steroid 3)

Synthesis
 Δ^5 -Androstene- $3\beta,7(\alpha\beta),17\beta$ -triol

5 Δ^5 -Androstene- $3\beta,7(\alpha\beta),17\beta$ -triol was
manufactured in accordance with the procedure set
forth in Example IV except that Step 2 was
eliminated with the dried filtrate from Step 1
simply resolublized in the 80 ml of methylene
10 chloride in preparation for Step 3.

Example VI
(Steroid 4)

Synthesis
 Δ^5 -Androstene- $3\beta,17\beta$ -diol-7-one

15 (Step 1) Into a 50 ml flask equipped with
a magnetic stirrer and a water bath was placed 6.5
ml acetic anhydride, 23 ml acetic acid, 1.7 grams
sodium acetate, and 2 grams androstenediol diacetate
to form a first mixture. Into the first mixture was
20 added 2 grams chromium trioxide over a thirty minute
period to form a second mixture. The first mixture
was maintained at a constant temperature of 56-58°C
and continuously agitated during addition of the
chromium trioxide. The second mixture was
25 maintained at 56-58°C and continuously agitated for
an additional hour after which the second mixture
was cooled and slowly poured with continuous
agitation into 600 ml of ice water to form a
precipitate. The flocculent precipitate was

- 32 -

filtered through a sintered glass funnel, washed with water until no longer green, and dried in vacuo.

(Step 2) The dried precipitate was
5 resolubilized in 500 ml of methanol in a one liter, round bottom flask equipped with a magnetic stirrer and reflux condenser to form a third mixture. The third mixture was placed under a N₂ atmosphere and heated under constant agitation to reflux. Into the
10 third mixture was added 250 ml of a 5% aqueous solution of Na₂CO₃ to form a fourth mixture. The fourth mixture was refluxed under constant agitation for 45 minutes. The methanol was rotovapped off and the aqueous fourth mixture carefully brought to a pH
15 of 7 with an appropriate amount of glacial acetic acid. The neutralized fourth mixture was extracted twice with 100 ml portions of dichloromethane and the combined dichloromethane extract evaporated in vacuo. The extracted solids were then
20 azeotropically dried first with absolute ethanol and then twice with acetone. Methanol was added to the dried extracted solids until the solids were completely dissolved to form a fifth mixture. Hexane was added to the fifth mixture until the
25 mixture began to cloud at which time crystals of Δ⁵-androstene-3β,17β-diol-7-one formed at room temperature.

- 33 -

The resultant product had a melting point of 200-202°C.

Example VII
(Steroid 5)

5

Synthesis
 Δ^5 -Androstene-3 β -acetoxy-7,16,17-trione

(Step 1) Into a 50 ml flask equipped with a magnetic stirrer and a water bath was placed 6.5 ml acetic anhydride, 23 ml acetic acid, 1.7 grams sodium acetate, and 2 grams DHEA acetate to form a first mixture. Into the first mixture was added 2 grams chromium trioxide over a thirty minute period to form a second mixture. The first mixture was maintained at a constant temperature of 56-58°C and continuously agitated during addition of the chromium trioxide.

10

(Step 2) The second mixture was maintained at 56-58°C and continuously agitated for an additional hour after which the second mixture was cooled and slowly poured under continuous agitation into 600 ml of ice water to form a precipitate. The flocculent precipitate was collected on a sintered glass funnel and washed with water until no longer green. After drying in vacuo over P₂O₅, the product was dissolved in methanol and recrystallized to yield substantially pure 3 β -acetoxy- Δ^5 -androstene-7,17-dione (51) having a melting point of 184-185°C.

20

25

- 34 -

(Step 3) Into a second 50 ml round bottom flask equipped with a magnetic stirrer and retained within a dry-ice bath was placed 1.00 gram (2.90 mmoles) of the 3 β -acetoxy- Δ^5 -androsterone-7,17-dione (51) and 20 ml neat tetrahydrofuran to form a third mixture. The third mixture was placed under a N₂ atmosphere. Into the third mixture was added 1.07 ml (8.43 mmoles) trimethylchlorosilane to form a fourth mixture. The fourth mixture was maintained under the N₂ atmosphere and cooled to -78°C.

(Step 4) Into a third 25 ml round bottom flask equipped with a magnetic stirrer and retained within a dry-ice bath was placed 1.07 ml (7.66 mmoles) diisopropyl amine, 3.60 ml of a 1.94M solution of n-butyllithium in hexane (6.96 mmoles), and 4 ml of tetrahydrofuran to form lithium diisopropyl amide. The solution (LDA solution) was prepared under a N₂ atmosphere at -78°C. The LDA solution was warmed slightly to dissolve any solids therein and then added, under a N₂ atmosphere, to the fourth mixture via cannula to form a fifth mixture.

(Step 5) The fifth mixture was removed from the dry-ice bath and allowed to warm to room temperature for 15 minutes at which time 1.25 ml triethylamine was added to the fifth mixture to form a sixth mixture. Into a separatory funnel was placed 40 ml hexane, 40 ml of a saturated NaHCO₃

- 35 -

aqueous solution, and the sixth mixture. The organic phase was extracted with hexane, washed with a saturated NaCl aqueous solution, dried over Na₂SO₄, and the solvent removed to yield 1.42 grams of a dry organic solid. The organic solid was identified by NMR (CDCl₃) as an approximately 70:30 mixture of 3 β -(trimethylsilyl)acetoxo-17-hydroxy- Δ 5, Δ 16-androstadiene-7-one trimethylsilyl ether (52b) and 3 β -acetoxo-17-hydroxy- Δ 5, Δ 16-androstadiene-7-one trimethylsilyl ether (52a). The results of the NMR analysis are set forth in Tables One & Two.

(Step 6) Into a fourth 100 ml round bottom flask equipped with a magnetic stirrer and retained within a dry-ice bath was placed 2.85 mmols of the organic solid obtained in Step 5, 20 ml neat tetrahydrofuran and 0.320 ml (4.00 mmole) neat pyridine to form a seventh mixture. The seventh mixture was cooled to -78°C and placed under a N₂ atmosphere. Into the seventh mixture was added 0.710 grams (3.71 mmols) of benzeneselenenyl chloride in 4 ml of tetrahydrofuran to form an eighth mixture.

(Step 7) Into a separatory funnel was placed a cosolvent system of a 0.5 N HCl aqueous solution and dichloromethane. Into the cosolvent system was added the eighth mixture to extract the organic phase. The second organic phase was extracted by dichloromethane, sequentially washed

- 36 -

with water and a saturated NaHCO_3 aqueous solution, dried over Na_2SO_4 and the solvent removed to yield 1.72 grams of an organic oil. The organic oil was separated by chromatography (100 grams silica eluted with hexane-ethyl acetate at 90:10 to 50:50 with 50 ml fractions) into 1.44 grams of first and second organic fractions (Fractions 14-17), diphenyl diselenide (Fractions 9-11) and unreacted 3β -acetoxy- Δ^5 -androstene-7,17-dione (51) (Fractions 18-19). The first and second organic fractions were identified by NMR as 3β -acetoxy-16*-phenylseleno- Δ^5 -androstene-7,17-dione (53a) and 3β -(trimethylsilyl)acetoxy-16-phenylseleno- Δ^5 -androstene-7,17-dione (53b) respectively. The results of the NMR analysis are set forth in Tables Three and Four.

(Step 8) Into a fifth 100 ml round bottom flask equipped with a magnetic stirrer was placed 25 ml ether, 5 ml dichloromethane and 1.19 mmoles of the second organic fraction obtained in Step 7 (53b) to form a ninth mixture. Into the ninth mixture was added 8 ml of a 10% aqueous solution of potassium fluoride and 3 ml of a 1M tetra-n-butylammonium fluoride solution in tetrahydrofuran to form a tenth mixture. The tenth mixture was maintained at 25°C and continuously agitated for two hours after which the tenth mixture was poured into an ether-hexane-water solvent system to extract the organic

- 37 -

phase. The extracted organic phase was washed twice with water, once with a saturated NaCl aqueous solution, dried over Na_2SO_4 and the solvent removed to yield 0.594 grams of 3β -acetoxy-16-phenylseleno-
5 Δ^5 -androstene-7,17-dione (53a).

(Step 9) Into a sixth 100 ml round bottom flask equipped with a magnetic stirrer was placed 25 ml dichloromethane and 1.10 mmoles of 3β -acetoxy-16-phenylseleno- Δ^5 -androstene-7,17-dione (53a) to form
10 an eleventh mixture. The eleventh mixture was cooled to 0°C and maintained under continuous agitation. Into the eleventh mixture was added 0.296 grams (1.2 mmoles) m-chloroperbenzoic acid (70%) followed five minutes later by 0.40 ml
15 dimethylsulfide to form a thirteenth mixture. The thirteenth mixture was washed 3 times with 50 ml of a cold NaHCO_3 aqueous solution and filtered through Na_2SO_4 .

(Step 10) Into a seventh 250 ml round
20 bottom flask equipped with a magnetic stirrer was placed 1.2 ml acetic anhydride, 1.2 ml pyridine and the liquid phase of the thirteenth mixture to form a fourteenth mixture. The fourteenth mixture was continuously agitated at room temperature for an
25 hour after which 60 ml of a saturated NaHCO_3 aqueous solution was added to form a fifteenth mixture having separate organic and inorganic layers. The fifteenth mixture was maintained under continuous

- 38 -

agitation until bubbling ceased. The organic layer was separated from the inorganic layer by drawing off the organic layer in a separatory funnel. The separated organic layer was washed with a saturated
5 NaHCO_3 aqueous solution, dried over Na_2SO_4 and the solvent removed to yield 0.713 grams of a dry organic solid. The organic solid was identified by NMR (CDCl_3) as a 90:10 mixture of $3\beta,16$ -diacetoxy-16-phenylseleno- Δ^5 -androstene-7,17-dione (55) and 3β -
10 acetoxy- Δ^5 -androstene-16-phenylseleno-16-m-chlorobenzoate-7,17-dione (54). The results of an NMR analysis of the (55) fraction in the mixture are set forth in Table Five.

(Step 11) Into a round bottom flask
15 equipped with a magnetic stirrer was placed 25 ml carbon tetrachloride and 1.10 mmoles of the 90:10 mixture of $3\beta,16$ -diacetoxy-16-phenylseleno- Δ^5 -androstene-7,17-dione (55) and 3β -acetoxy- Δ^5 -androstene-16-phenylseleno-16-m-chlorobenzoate-7,17-
20 dione (54) to form a sixteenth mixture. Into the sixteenth mixture was added 0.12 ml pyridine, 10 mg benzeneseleninic acid, and 19 mg diphenyldiselenide to form a seventeenth mixture. The seventeenth mixture was maintained under vigorous agitation and
25 3.4 ml of a 15% H_2O_2 aqueous solution added to form an eighteenth mixture. The eighteenth mixture was agitated continuously for 45 minutes after which the eighteenth mixture was washed twice with a saturated

- 39 -

NaHCO₃ aqueous solution and dried in vacuo to yield 0.390 grams of an organic solid. The organic solid was separated by chromatography (50 grams silica gel eluted with 50% hexane-ethyl acetate with 25 ml fractions) to yield 0.236 grams of an organic fraction (Fractions 9-10). The organic fraction was identified by NMR as pure 3 β ,16-diacetoxy- Δ 5, Δ 15-androstadiene-7,17-dione (57). The results of the NMR analysis are set forth in Table Six.

(Step 12) Into a round bottom flask equipped with a magnetic stirrer was placed 1.03 mmoles of 3 β ,16-diacetoxy- Δ 5, Δ 15-androstadiene-7,17-dione (57) and 15 ml methanol to form a nineteenth mixture. Into the nineteenth mixture was placed 0.500 ml triethylamine to form a twentieth mixture. The twentieth mixture was placed under a N₂ atmosphere and maintained under constant agitation for 16 hours. The twentieth mixture was then extracted between H₂O and CH₂Cl₂. The organic layer was washed twice with a saturated NaHCO₃ aqueous solution, and then dried and evaporated under reduced pressure to yield 0.281 grams of a yellow organic solid. The organic solid was identified by NMR as a mixture of organic compounds including about 65% 3 β -acetoxy- Δ 5-androstene-7,16,17-trione (5). The results of the NMR analysis are set forth in Table Seven.

- 40 -

Example VIII
(Steroid 6)

Synthesis

3 β ,16 α -dihydroxy- Δ 5-androstene-7,17-dione

5 (Step 1) Into a round bottom flask
equipped with a magnetic stirrer was placed 2.80
mmoles of 3 β -propionoxy-17-hydroxy- Δ 5, Δ 16-
androstadiene-7-one trimethylsilyl ether (62)
synthesized in accordance with the procedure set
10 forth in Example VII and identified by NMR (See
Table Nine) and 40 ml of tetrahydrofuran to form a
first mixture which was cooled to 0° in an ice bath.
Into the first mixture was placed 2.95 mmoles of m-
chloroperbenzoic acid (80-90%) to form a second
15 mixture. The second mixture was warmed to 25°C and
maintained under constant agitation for 10 min.

(Step 2) The second mixture was
continuously agitated and 40 ml of a 1N HCl aqueous
solution added to form a third mixture which was
20 maintained under constant agitation for 20 min. The
third mixture was partitioned between ether and
water and separated by decanting the ether phase
from the water phase. The ether phase was washed
with a saturated NaHCO₃ aqueous solution, then a
25 saturated NaCl aqueous solution, and dried in vacuo
to yield an organic solid. The organic solid was
purified by chromatography (140 gm of silica eluted
with 60:40 to 70:30 ethyl acetate-hexane with 25 ml
fractions) to give 0.586 gm of a first organic

- 41 -

compound. The first organic compound was identified by NMR as 3β -propionoxy- 16α -hydroxy- Δ^5 -androstene-7,17-dione (63). The results of the NMR analysis are set forth in Table Ten.

5 (Step 3) In a second round bottom flask equipped with a magnetic stirrer was placed 0.155 mmoles of 3β -propionoxy- 16α -hydroxy- Δ^5 -androstene-7,17-dione (63) dissolved in 6 ml of methanol to form a third mixture. To this third mixture was
10 added 1.5 ml of an aqueous solution of 6N sulfuric acid to form a fourth mixture which was maintained at 25°C for 18 hours. The fourth mixture was then partitioned between ethyl acetate and water and separated by decanting the ethyl acetate phase from
15 the water phase. The ethyl acetate was evaporated to yield an organic product which was purified by chromatography (silica preparative plate eluted three times with 60% ethyl acetate-hexane) to yield 18 mg of an organic compound which was then
20 dissolved in and crystallized from methanol to give 6 mg of substantially pure material having a melting point of 235-239°C. The organic compound was identified by NMR as 3β , 16α -dihydroxy- Δ^5 -androstene-7,17-dione (6). The results of the NMR analysis are
25 set forth in Table Eleven.

Example IX
(Steroid 7)

- 42 -

Synthesis Δ^5 -Androstene-3 β -propionoxy-16 β -acetoxy-7,17-dione

(Step 1) Into a round bottom flask equipped with a magnetic stirrer was placed 1.52
5 mmoles of 3 β -propionoxy-16 α -hydroxy- Δ^5 -androstene-7,17-dione, 3.0 mmoles of triphenylphosphine, 6.0 mmoles of acetic acid in 11 ml of tetrahydrofuran. This first mixture was placed under N₂ and cooled to 0°C in an ice bath. To the first mixture was added
10 3.0 mmoles of diethyl azodicarboxylate dropwise to form a second mixture. The second mixture was warmed to 25°C and maintained at this temperature for 18 hr. It was then partitioned between ether-hexane and water. The ether-hexane layer was washed
15 with water, water, saturated NaHCO₃ aqueous solution, saturated NaCl aqueous solution, dried over Na₂SO₄ and evaporated to give an organic solid which was purified by chromatography on 130 gm silica eluted with ethyl acetate-hexane (20:80 to 50:50) with 25
20 ml fractions and crystallized from dichloromethane-hexane to yield 0.267 gm of an organic compound. The organic compound was identified by NMR as 3 β -propionoxy-16 β -acetoxy- Δ^5 -androstene-7,17-dione containing ~ 20% of the 16 α epimer. The results of
25 the NMR analysis are set forth in Table Twelve.

(Step 2) Conversion to Δ^5 -androstene-3 β ,16 β -dihydroxy-7,17-dione can be done as described in Example VIII.

30 **Example X**
(Steroid 8)

Synthesis Δ^5 -Androstene-3 β ,7 α ,17 β -triol-16-one

- 43 -

(Step 1) Into a 100 ml round bottomed flask was placed 3 grams (7.7 mmoles) of 3 β ,16 α -diacetoxo DHEA (prepared in accordance with the procedure set forth in Numazawa, M. and Osawa, Y. Steroids, vol. 32, p 519 (1978)) and 3.5 grams NaHCO₃ in 50 ml of hexane to form a first mixture. The first mixture was stirred and heated to reflux under a N₂ atmosphere. To the first mixture was added 1.6 grams dibromantin (1,3-dibromo-5,5-dimethylhydantoin) to form a second mixture.

(Step 1) The second mixture was stirred, refluxed for 30 minutes, and then cooled to room temperature. The refluxed second mixture was filtered to remove solids and washed with CH₂Cl₂. The resultant filtrate was concentrated to near dryness in vacuo using a water bath maintained below 35°C.

(Step 3) The dried filtrate was resolubilized in 21 ml of toluene in a one liter stoppered flask equipped with a magnetic stirrer and placed in an ice bath. Into the resolubilized filtrate was added 2.1 grams anhydrous LiBr in 80 ml ice-cold acetone to form a third mixture. The third mixture was shielded from light and stirred continuously for three hours at 0°C. The resulting mixture containing predominantly 7 α -bromo was used immediately in step four.

- 44 -

(Step 4) Into a 500 ml flask equipped with a magnetic stirrer was placed 80 ml dichloromethane, 21 ml glacial acetic acid, and 6.7 grams of silver acetate to form a first suspension. The first suspension was stirred continuously for 20 minutes at room temperature. The stirred first suspension was added under constant agitation into the warmed third mixture to form a second suspension. The second suspension was constantly stirred for 30 minutes at room temperature after which the suspension was filtered through a sintered glass funnel to separate a solid residue. The filtrate was concentrated to yield an oily residue.

(Step 5) To the oily residue was added 300 ml H₂O and sufficient NaHCO₃ to achieve a fourth mixture with a neutral pH. The fourth mixture was extracted five times with 150 ml of ethyl acetate, the organic layers combined, washed with brine, dried over MgSO₄ and concentrated to dryness.

(Step 6) The crude organic phase was separated by chromatography (silica gel eluted with ethyl acetate : pet ether at 1:3, 1:2 and 1:1) to yield 700 mg (20%) of a first organic fraction and 1.5 grams (48%) of a second organic fraction. After crystallization from diethyl ether the first (mp 170-172 °C) and second (mp 155-158 °C) organic fractions were identified by NMR as Δ⁵-androstene-3β,7α,16α-triacetoxy-17-one and the corresponding

- 45 -

Δ^5 -androstene- 3β , 16α -diacetoxy- 7α -ol-17-one (83) respectively. The results of the NMR analysis of these two compounds are set forth in Tables Thirteen and Fourteen.

5 (Step 7) Into a flask equipped with a magnetic stirrer was added 400 mg (1 mmole) of the Δ^5 -Androstene- 3β , 16α -diacetoxy- 7α -hydroxy-17-one (83) and 342 mg of K_2CO_3 in 25 ml of methanol at room temperature to form a fifth mixture. The fifth
10 mixture was stirred for two hours. The alkaline solution enolized the 17-keto to form the more stable 17-hydroxy-16-one compound. Δ^5 -Androstene- 3β , 7α ,17-trihydroxy-16-one (8) was isolated from the fifth mixture by filtering to remove the insoluble
15 salt, evaporating the methanol in vacuo, purifying the organic residue over silica gel and crystallizing the organic compound from methanol-ethyl ether solution. The crystallized organic fraction (180 mg, 56%; mp:>230°C) was identified by
20 NMR as Δ^5 -androstene- 3β , 7α ,17-trihydroxy-16-one (8). The results of the NMR analysis are set forth in Table Fifteen.

Example XI
(Steroid 9)

25

Synthesis
 Δ^5 -Androstene- 3β , 17β -diol-7,16-dione

- 46 -

(Step 1) Into a round bottom flask equipped with a magnetic stirrer was added 1.05 grams (2.80 mmoles) Δ^5 -androstene-3 β -propionoxy-16 α -hydroxy-7,17-dione (63), 80 ml methanol and 40 ml of a 5% aqueous Na_2CO_3 solution while stirring rapidly to form a first mixture. The first mixture was stirred for 42 hours after which the methanol was evaporated and a combination of 100 ml of water and 2 ml of acetic acid added to form a second mixture. A solid material was filtered from the second mixture, resolubilized in methanol and then crystallized to yield 0.324 gm of an organic compound.

A small sample of the organic compound was again recrystallized from methanol to produce a purified sample having a melting point of 215-218°C. The first organic compound was identified by NMR as Δ^5 -androstene-3 β ,17 β -diol-7,16-dione. The results of the NMR analysis are set forth in Table Sixteen.

- 47 -

Table One

NMR Results

3 β -acetoxy-17-hydroxy- Δ^5,Δ^{16} -androstadiene-
7-one-trimethylsilyl ether (52a)

<u>Conditions</u>	<u>Peak</u>	<u>Significance</u>
(δ) CDCl ₃ 270 MHz	0.21	s, O-SiMe ₃
	0.87	s, 18-CH ₃
	1.25	s, 19-CH ₃
	2.07	s, CH ₃ C=O
	2.75	ddd, J=14,6,3, Hz 15 α -H
	4.54	dd, J=3,1.5 Hz 16-H
	4.73	tt, J=11,5 Hz 3 α -H
	5.76	d, J=2 Hz 6-H

- 48 -

Table Two

NMR Results

3 β -(trimethylsilyl)acetoxy-17-hydroxy-
 Δ^5,Δ^{16} -androstadiene-7-one trimethylsilyl ether (52b)

<u>Conditions</u>	<u>Peak</u>	<u>Significance</u>
(δ) CDCl ₃ 270 MHz	0.13	s, C-SiMe ₃
	0.21	s, O-SiMe ₃
	0.87	s, 18-CH ₃
	1.25	s, 19-CH ₃
	1.90	s, CH ₂ -Si
	2.75	ddd, J=14,6,3, Hz 15 α -H
	4.54	dd, J=3,1.5 Hz 16-H
	4.73	tt, J=11,5 Hz 3 α -H
	5.76	d, J=2 Hz 6-H

- 49 -

Table Three

NMR Results

3 β -acetoxy-16 α -phenylseleno-
 Δ 5-androstene-7,17-dione (53a)

<u>Conditions</u>	<u>Peak</u>	<u>Significance</u>
(δ) CDCl ₃ 270 MHz	0.92	s, 18-CH ₃
	1.21	s, 19-CH ₃
	2.07	s, CH ₃ COO
	3.00	ddd, J=14, 5, 0.5 Hz 15 α -H
	4.10	d, J=7.5 Hz J _{SeH} =5 Hz 16 β -H
	4.73	tt, J=11, 5 Hz 3 α -H
	5.74	d, J=1.5 Hz 6-H
	7.31	m, SePh
	7.68	m, SePh

- 50 -

Table Four

NMR Results

3 β -(trimethylsilyl)acetoxy-16 α -phenylseleno-
 Δ 5-androstene-7,17-dione (53b)

<u>Conditions</u>	<u>Peak</u>	<u>Significance</u>
(δ) CDCl ₃ , 200 MHz	0.13	s, C-SiMe ₃
	0.91	s, 18-CH ₃
	1.21	s, 19-CH ₃
	1.91	s, CH ₂ Si
	3.00	ddd, J=14 5.5, 0.5 Hz 15 α -H
	4.10	d, J=7.5 Hz J _{SeH} =5 Hz 16 β -H
	4.73	tt, J=10.5 Hz 3 α -H
	5.74	d, J=1.5 Hz 6-H
	7.32	m, SePh
	7.68	m, SePh

- 51 -

Table Five

NMR Results

3 β ,16-diacetoxy- Δ 5-androstene-
16-phenylseleno-7,17-dione (55)

<u>Conditions</u>	<u>Peak</u>	<u>Significance</u>
(δ) CDCl ₃ , 200 MHz	1.25	s, 18-CH ₃
	1.35	s, 19-CH ₃
	2.05	s, 3-CH ₃ COO
	2.09	s, 16-CH ₃ COO
	3.20	dd, J=14.5, 6 Hz 15 α -H
	4.73	tt, J=11, 5.5 Hz 3 α -H
	5.74	d, J=1.5 Hz 6-H
	7.35	m, SePh
	7.68	m, SePh

- 52 -

Table Six

NMR Results

3 β ,16-diacetoxy- Δ^5 , Δ^{15} -androsteradiene-
7,17-dione (57)

<u>Conditions</u>	<u>Peak</u>	<u>Significance</u>
(δ) CDCl ₃ 200 MHz	1.24	s, 18-CH ₃
	1.30	s, 19-CH ₃
	2.07	s, 3-CH ₃ COO
	2.25	s, 16-CH ₃ COO
	4.75	tt, J=11,5 Hz 3 α -H
	5.83	d, J=1.5 Hz 6-H
	7.82	broad s, 15-H

- 53 -

Table Seven

NMR Results

 3β -acetoxy- Δ^5 -androstene-7,16,17-trione (5)

<u>Conditions</u>	<u>Peak</u>	<u>Significance</u>
(δ) CDCl ₃ 270 MHz	1.07	s, 18-CH ₃
	1.30	s, 19-CH ₃
	2.05	s, 3-CH ₃ COO
	2.44	dd, J=18.5, 8 Hz 15β-H
	2.61	m, 4-H
	3.43	dd, J=18.5, 6.5 Hz 15α-H
	4.75	tt, J=11, 5 Hz 3α-H
	5.80	d, J=1.5 Hz 6-H

- 54 -

Table Eight

NMR Results

 3β -propionoxy- Δ^5 -androstene-7,17-dione (61)

<u>Conditions</u>	<u>Peak</u>	<u>Significance</u>
(δ) CDCl ₃ 270 MHz	0.91	s, 18-CH ₃
	1.16	t, J=7.5 Hz <u>CH₃CH₂COO</u>
	1.25	s, 19-CH ₃
	2.15	dt, J=19, 8.5 Hz 16α-H
	2.33	q, J=7.5 Hz <u>CH₃CH₂COO</u>
	2.83	dddd, J=15.5, 8.5, 4, 1 Hz 15α-H
	4.75	tt, J=11, 5 Hz 3α-H
	5.77	d, J=2 Hz 6-H

- 55 -

Table Nine
NMR Results
3 β -propionoxy-17-hydroxy- Δ^5,Δ^{16} -
androstadiene-7-one trimethylsilyl ether (62)

<u>Conditions</u>	<u>Peak</u>	<u>Significance</u>
(δ) CDCl ₃ 270 MHz	0.18	s, Si-Me ₃
	0.85	s, 18-CH ₃
	1.13	t, J=7.5 Hz <u>CH₃CH₂COO</u>
	1.21	s, 19-CH ₃
	2.14	ddd, J=14.8, 10.7, 1.5 Hz 15 β -H
	2.31	q, J=7.5 Hz <u>CH₃CH₂COO</u>
	2.71	ddd, J=14.8, 6.4, 2.1 Hz 15 α -H
	4.52	dd, J=3.1, 1.5 Hz 16-H
	4.72	tdd, J=11.4, 5.3, 4.4 Hz 3 α -H
	5.71	d, J=1.6 Hz 6-H

- 56 -

Table Ten

NMR Results

3 β -propionoxy-16 α -hydroxy- Δ 5
-androstene-7,17-dione (63)

<u>Conditions</u>	<u>Peak</u>	<u>Significance</u>
(δ) CDCl ₃ 270 MHz	1.00	s, 18-CH ₃
	1.15	t, J=7.5 Hz CH ₃ CH ₂ COO
	1.23	s, 19-CH ₃
	2.33	q, J=7.5 Hz CH ₃ CH ₂ COO
	2.75	ddd, J=13.5, 6.5, 1.5 Hz 15 α -H
	4.42	d, J=8 Hz 16 β -H
	4.76	tt, J=10.5, 4.5 Hz 3 α -H
	5.77	d, J=1.5 Hz 6-H

- 57 -

Table Eleven

NMR Results

3 β ,16 α -dihydroxy-
 Δ 5-androstene-7,17-dione (6)

<u>Conditions</u>	<u>Peak</u>	<u>Significance</u>
(6) CDCl ₃ , 270 MHz	1.00	s, 18-CH ₃
	1.23	s, 19-CH ₃
	2.26	ddd, J=14.5, 10.5, 8.6 Hz 15 β -H
	2.55	ddd, J=14.1, 5.0, 1.3 Hz 4 α -H
	2.76	ddd, J=14.6, 6.9 1.4 Hz 15 α -H
	3.69	broad t, J=11 Hz 3 α -H
	4.41	d, J=8.5 Hz 16 β -H
	5.75	d, J=1.7 Hz 6-H

- 58 -

Table Twelve

NMR Results

3 β -propionoxy-16 β -acetoxy- Δ 5
-androstene-7,17-dione (7)

<u>Conditions</u>	<u>Peak</u>	<u>Significance</u>
(δ) CDCl ₃ 270 MHz	1.00	s, 18-CH ₃
	1.15	t, J=7.5 Hz CH ₃ CH ₂ COO
	1.25	s, 19-CH ₃
	2.12	s, CH ₃ COO
	2.33	q, J=7.5 Hz CH ₃ CH ₂ COO
	3.35	ddd, J=11, 8.5 4 Hz 15 α -H
	4.74	tt, J=11, 4 Hz 3 α -H
	5.77	d, J=1.5 Hz 6-H

- 59 -

Table Thirteen

NMR Results

Δ^5 -Androstene-3 β ,16 α -diacetoxy-
7 α -hydroxy-17-one (83)

<u>Conditions</u>	<u>Peak</u>	<u>Significance</u>
(δ) CDCl ₃ 300 MHz	0.98	s, CH ₃
	1.02	s, CH ₃
	2.02	s, 2xCO ₂ CH ₃
	2.10	s, CO ₂ CH ₃
	4.70	m, 1H, 3-H
	5.02	dd, 1H, J=2 Hz 7-H
	5.40	d, 1H, J=4 Hz 16-H
	5.61	d, 1H, J=2 Hz 6-H

- 60 -

Table Fourteen

NMR Results

Δ^5 -androstene- 3β , 16α -diacetoxy
- 7α -ol-17-one

<u>Conditions</u>	<u>Peak</u>	<u>Significance</u>
(δ) CDCl ₃ 300 MHz	0.97	s, CH ₃
	1.02	s, CH ₃
	2.04	s, CO ₂ CH ₃
	2.15	s, CO ₂ CH ₃
	3.92	m, 1H, 7-H
	4.63	m, 1H, 3-H
	5.44	d, 1-H, J=5 Hz 16-H
	5.64	d, 1-H, J=4 Hz 6-H

- 61 -

Table Fifteen

NMR Results

 Δ^5 -androstene-3 β ,7 α ,17-trihydroxy-16-one (8)

<u>Conditions</u>	<u>Peak</u>	<u>Significance</u>
(δ) DMSO 300 MHz	0.61	s, CH ₃
	0.92	s, CH ₃
	3.32	m, 3-H
	3.60	broad s 1H, 7-H
	3.64	s, 1H, 16-H
	4.26	d, 1H, J=2 Hz OH, D ₂ O exch.
	4.68	broad s, 1H OH, D ₂ O exch.
	5.30	broad s, 1H OH, D ₂ O exch.
	5.42	d, 1H, J=2 Hz 6-H

- 62 -

Table Sixteen

NMR Results

3 β ,17 β -dihydroxy- Δ 5
-androstene-7,16-dione (9)

<u>Conditions</u>	<u>Peak</u>	<u>Significance</u>
(δ) CDCl ₃ 270 MHz	0.75	s, 18-CH ₃
	1.26	s, 19-CH ₃
	3.15	ddd, J=19,7, 1.5 Hz 15 α -H
	3.72	tt, J=10, 4.5 Hz 3 α -H
	3.78	broad s 17 α -H
	5.77	d, J=1.5 Hz 6-H

- 63 -

I claim:

1. A treatment method comprising the step of treating a subject in need of such treatment with an effective *weight gain preventative* amount of a steroid selected from the group consisting of

Δ^5 -Androstene- 3β -acetoxy-7,16,17-trione

Δ^5 -Androstene- 3β , 16α -dihydroxy-7,17-dione

Δ^5 -Androstene- 3β -propionoxy- 16β -acetoxy-7,17-dione

Δ^5 -Androstene- 3β , 7α , 17β -triol-16-one

Δ^5 -Androstene- 3β , 17β -diol-7,16-dione

Δ^5 -Androstene- 3β , 16α , 17β -triol,7-one

and derivatives thereof wherein one or more of the hydroxyl or keto substituents is a group convertible thereto by hydrolysis.

2. The treatment method of claim 1 wherein the step of treating a subject comprises the step of treating a mammal.

3. The treatment method of claim 2 wherein the step of treating a mammal comprises the step of treating a human.

4. The treatment method of claim 3 wherein the step of treating a human with an effective *weight gain preventative* amount of a steroid comprises the step of treating the human with about 0.1 to 2 grams of the steroid per 100 kg body weight per day.

- 64 -

5. The treatment method of claim 3 wherein the step of treating a human with an effective *weight gain preventative* amount of a steroid comprises the step of administering a therapeutic dose of the steroid to the human at least once a week.
6. The treatment method of claim 3 wherein the step of treating a human with an effective *weight gain preventative* amount of a steroid comprises the step of administering a therapeutic dose of the steroid to the human at least once a day.
7. The treatment method of claim 3 wherein the step of treating a human with an effective *weight gain preventative* amount of a steroid comprises the step of injecting the human with a therapeutic dose of the steroid.
8. The treatment method of claim 3 wherein the step of treating a human with an effective *weight gain preventative* amount of a steroid comprises the step of inducing the human to ingest a therapeutic dose of the steroid.
9. A treatment method comprising the step of treating a subject in need of such treatment with an effective *weight reduction promoting* amount of a steroid selected from the group consisting of

- 65 -

Δ^5 -Androstene- 3β -acetoxy-7,16,17-trione
 Δ^5 -Androstene- 3β , 16α -dihydroxy-7,17-dione
 Δ^5 -Androstene- 3β -propionoxy- 16β -acetoxy-7,17-dione
 Δ^5 -Androstene- 3β , 7α , 17β -triol-16-one
 Δ^5 -Androstene- 3β , 17β -diol-7,16-dione
 Δ^5 -Androstene- 3β , 16α , 17β -triol,7-one

and derivatives thereof wherein one or more of the hydroxyl or keto substituents is a group convertible thereto by hydrolysis.

10. The treatment method of claim 9 wherein the step of treating a subject comprises the step of treating an overweight human.

11. A method of treating obesity comprising the step of treating an *obese subject* with a therapeutic amount of a steroid selected from the group consisting of

Δ^5 -Androstene- 3β -acetoxy-7,16,17-trione
 Δ^5 -Androstene- 3β , 16α -dihydroxy-7,17-dione
 Δ^5 -Androstene- 3β -propionoxy- 16β -acetoxy-7,17-dione
 Δ^5 -Androstene- 3β , 7α , 17β -triol-16-one
 Δ^5 -Androstene- 3β , 17β -diol-7,16-dione
 Δ^5 -Androstene- 3β , 16α , 17β -triol,7-one

and derivatives thereof wherein one or more of the hydroxyl or keto substituents is a group convertible thereto by hydrolysis.

- 66 -

12. The treatment method of claim 11 wherein the step of treating a subject comprises the step of treating a human.

13. A biologically active steroid effective for promoting weight control without suppressing appetite or promoting the synthesis of sex hormones comprising Δ^5 -androstene- 3β -acetoxy-7,16,17-trione and derivatives thereof wherein one or more of the hydroxyl or keto substituents is a group convertible thereto by hydrolysis.

14. A biologically active steroid effective for promoting weight control without suppressing appetite or promoting the synthesis of sex hormones comprising Δ^5 -androstene- 3β , 16α -dihydroxy-7,17-dione and derivatives thereof wherein one or more of the hydroxyl or keto substituents is a group convertible thereto by hydrolysis.

15. A biologically active steroid effective for promoting weight control without suppressing appetite or promoting the synthesis of sex hormones comprising Δ^5 -androstene- 3β -propionoxy- 16β -acetoxy-7,17-dione and derivatives thereof wherein one or more of the hydroxyl or keto substituents is a group convertible thereto by hydrolysis.

- 67 -

16. A biologically active steroid effective for promoting weight control without suppressing appetite or promoting the synthesis of sex hormones comprising Δ^5 -androstene- $3\beta,7\alpha,17\beta$ -triol-16-one and derivatives thereof wherein one or more of the hydroxyl or keto substituents is a group convertible thereto by hydrolysis.

17. A biologically active steroid effective for promoting weight control without suppressing appetite or promoting the synthesis of sex hormones comprising Δ^5 -androstene- $3\beta,17\beta$ -diol-7,16-dione and derivatives thereof wherein one or more of the hydroxyl or keto substituents is a group convertible thereto by hydrolysis.

18. A biologically active steroid effective for promoting weight control without suppressing appetite or promoting the synthesis of sex hormones comprising Δ^5 -androstene- $3\beta,16\alpha,17\beta$ -triol,7-one and derivatives thereof wherein one or more of the hydroxyl or keto substituents is a group convertible thereto by hydrolysis.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/09852

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/56; C07C 49/105,49/293

US CL :514/177,178; 568/369,372

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/177,178; 568/369,372

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS

SEARCH TERMS: ANDROSTENE (P) OBESITY

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A 5,028,631 (SCHWARTZ ET AL.) 02 JULY 1991, SEE ENTIRE DOCUMENT.	1-18

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

Special categories of cited documents:	
A document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
E earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	*A* document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

29 OCTOBER 1994

Date of mailing of the international search report

DEC 06 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

THEODORE J. GRIARES

Telephone No. (703) 308-1235